FDA Approves Roche-Developed Blood Test for Alzheimer’s Signs
Eli Lilly secured FDA approval for Elecsys pTau217, a Roche-developed blood test that detects an Alzheimer-associated biomarker in adults 55 and older with cognitive decline. The result supports whether brain changes are likely or unlikely but is not a standalone diagnosis. By reducing reliance on costly scans or spinal-fluid tests, the approval could improve access to earlier screening as therapies roll out.